DePuy Orthopaedics Newswire

Comprehensive Real-Time News Feed for DePuy Orthopaedics.

Results 1 - 20 of 395 in DePuy Orthopaedics

  1. Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit...Read the original story w/Photo

    21 hrs ago | PRWeb

    ... litigation in the U.S. District Court, Northern District of Texas before Judge Ed Kinkeade. (In Re: DePuy Orthopaedics, Inc., Pinnacle Hip Implant Products Liability Litigation, MDL No. 2244) The attorneys at Wright & Schulte LLC are currently ...

    Comment?

  2. As DePuy Pinnacle Lawsuits Move Forward in U.S. Courts, Bernstein...Read the original story w/Photo

    Friday Sep 12 | PRWeb

    ... Liebhard LLP partner, Jeffrey S. Grand, is serving on the Plaintiffs' Steering Committee. (In re: DePuy Orthopaedics Inc. Pinnacle Hip Implant Product Liability Litigation, MDL No. 2244) The first federal trial of a Pinnacle hip replacement claim is ...

    Comment?

  3. Taiwan baby products market: Johnson & Johnson and BA1 4bchen the...Read the original story w/Photo

    Friday Sep 12 | PR-inside.com

    These include Johnson & Johnson, BA1 4bchen, Sebamed, Chicco and Pigeon, which together accounted for 71% of total sales in 2012. International brands have a higher acceptance amongst parents.

    Comment?

  4. Paulson, Mindich and Soros Bought Covidien; Should You?Read the original story

    Thursday Sep 11 | GuruFocus.com

    In this article, let's take a look at Covidien PLC . , a $41.12 billion market cap company, that develops, makes and distributes medical devices and supplies and other health care products.

    Comment?

  5. China orthopedic instrument market: RMB 9.8 billion industry estimated during 2012Read the original story w/Photo

    Wednesday Sep 10 | PR-inside.com

    Trauma products, spine products and joint products constitute the three major market segments of Chinese orthopedic instrument industry. In 2012, the three principal products accounted for an aggregate market share of about 82.2%, of which, trauma products showed the highest, approximately 35.5%, with market size up 18.24% YoY; spine and joint products ranked second and third , respectively.

    Comment?

  6. Jewish Hospital awarded grant to fight childhood obesityRead the original story w/Photo

    Wednesday Sep 10 | WHAS11

    LOUISVILLE, Ky. Jewish Hospital has received a major grant to help fight childhood obesity.

    Comment?

  7. A Top Dividend Stock for Your Portfolio: Johnson & JohnsonRead the original story

    Wednesday Sep 10 | The Motley Fool

    Dividend stocks are an essential ingredient to a well-balanced portfolio. Even so, it's important to bear in mind that not all dividend stocks are created equal.

    Comment?

  8. Germany baby products market: Johnson & Johnson the leading industry...Read the original story w/Photo

    Tuesday Sep 9 | PR-inside.com

    It was followed by NestlA Deutschland with a 15% value share, Procter & Gamble Germany & Co Operations with an 8% value share and Hipp with a 4% value share. All of the top four companies offer a wide range of attractive baby and child-specific products with competitive prices.

    Comment?

  9. Bristol-Myers Needs a Healthy Growth Shot to Justify Its ValuationRead the original story w/Photo

    Tuesday Sep 9 | TheStreet.com

    With shares around $51 and down nearly 4% on the year to date, Bristol-Myers investors could have done much better elsewhere -- Johnson & Johnson , for instance. Johnson & Johnson stock has posted gains of 16% and beating the health care sector's 11% gain, according to Morningstar.

    Comment?

  10. Interesting January 2015 Stock Options for Johnson & JohnsonRead the original story w/Photo

    Monday Sep 8 | Forbes.com

    Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson . So this week we highlight one interesting put contract, and one interesting call contract, from the January 2015 expiration for JNJ.

    Comment?

  11. GlaxoSmithKline's Experimental Ebola Vaccine Protects Monkeys For 10 MonthsRead the original story

    Monday Sep 8 | BioSpace

    An experimental Ebola vaccine similar to one being developed by GlaxoSmithKline is effective for at least five weeks in lab monkeys but requires boosting with an additional vaccine to extend its protection to 10 months, according to a study published on Sunday. The findings offer an early hint of which, if any, of the Ebola vaccines in development will prove effective, and in what form.

    Comment?

  12. Peril, Not Progress on Transatlantic Trade DealRead the original story

    Monday Sep 1 | Pharmaceutical Executive

    Only a year ago, hopes were high of rapid progress towards a transatlantic trade deal that would boost the European and US economies - and ease conditions for drug firms on both sides of the ocean. TTIP, the Transatlantic Trade and Investment Partnership, was the hot tip for a 2014 success story.

    Comment?

  13. Target, Wal-Mart call out suppliers on sustainabilityRead the original story w/Photo

    Monday Sep 8 | Business Journal

    Target Corp. and Wal-Mart Stores Inc. said last week that they're both pushing manufacturers to develop more organic and earth-friendly beauty and personal-care products.

    Comment?

  14. Most advertisers unhappy with programmatic tradingRead the original story

    Monday Sep 8 | Brand Republic

    Almost 80 per cent of advertisers are unhappy with programmatic trading due to lack of transparency, according to The World Federation of Advertisers . More than 70 per cent of advertisers prefer the "traditional" way of ad trading, due to the lack of pricing information, masked inventory sources and murky trading platform bidder strategies offered on agency trading desks.

    Comment?

  15. Johnson & Johnson accelerates Ebola vaccine programRead the original story

    Friday Sep 5 | Hispanic Business

    CEO says #JNJ will offer science & humanitarian aid to help with #Ebola crisis: http://t.co/uRQ0JOYsNF pic.twitter.com/DkOhEuGV1L -- Ebola Response Roadmap, which "aims to stop ongoing Ebola transmission worldwide within 6 -- 9 months, while rapidly managing the consequences of any further international spread." The company says the vaccine has worked well on macaque monkeys and targets the and given the evident, huge unmet medical need, we are stepping up our efforts and accelerating the Ebola program currently in pre-clinical development," said .

    Comment?

  16. Target, Wal-Mart call out suppliers on sustainabilityRead the original story w/Photo

    Friday Sep 5 | Business Journal

    Target Corp. and Wal-Mart Stores Inc. said Thursday that they're both pushing manufacturers to develop more organic and earth-friendly beauty and personal-care products. The rival retailers, together with sustainable-development group Forum for the Future, hosted an event Thursday in Chicago to bring together suppliers such as Procter & Gamble , Unilever , L'Oreal and Johnson & Johnson.

    Comment?

  17. The First Bellwether Trial in the DePuy Orthopaedics Litigation...Read the original story w/Photo

    Friday Sep 5 | PRWeb

    ... to protecting the rights of victims injured by defective medical devices, notes that Johnson & Johnson's DePuy Orthopaedics unit is facing its first bellwether trial over its Pinnacle hip device. The case is Herlihy-Paoli v. DePuy Orthopaedics Inc., ...

    Comment?

  18. Bristol-Myers Squibb's Eliquis Takes Aim at Johnson & JohnsonRead the original story w/Photo

    Thursday Sep 4 | The Motley Fool

    Eliquis, a factor Xa inhibitor used by doctors to prevent blood clots in heart disease patients and patients following orthopedic surgery, is quickly gaining ground on Johnson & Johnson's Xarelto, a billion-dollar blockbuster the company rolled out in 2011. Since Eliquis sales are jumping and pose a potential threat to Johnson & Johnson's market share, let's take a closer look.

    Comment?

  19. Johnson & Johnson to Quicken Development of Ebola VaccineRead the original story w/Photo

    Wednesday Sep 3 | Wall Street Journal

    Johnson & Johnson said Thursday it is accelerating the development of a vaccine regimen against Ebola, in an effort to help curb the virus that has overwhelmed West Africa. The regimen consists of two vaccine components from Johnson & Johnson's Crucell NV and Denmark-based biotech company Bavarian Nordic, both of which are developing vaccines against filoviruses, including Ebola.

    Comment?

  20. J&J Unit Ran - Amok' Marketing Pinnacle Hips, Jury Is ToldRead the original story

    Wednesday Sep 3 | The Washington Post

    ... ty by marketing flawed hips was "utter and complete nonsense," Sarver added. The case is Herlihy-Paoli v. DePuy Orthopaedics Inc., 12- cv-3590, U.S. District Court, Northern District of Texas (Dallas).

    Comment?